Back to Portfolio


Lifesaving Liver Disease Medicines

Versantis is a Zurich-based pharmaceutical company developing breakthrough liver disease medicines and diagnostics addressing high unmet medical needs.

Its lead candidate, VS-01, is currently at preclinical stage and has the potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 targets 3 rare indications and received an Orphan Drug Designation in ALF. In addition, Versantis’ pipeline promises to improve patients’ outcome in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities and significant upsides for Versantis.


Homepage LinkedIn Twitter  


Versantis in the News:

Redalpine leads Series A for health-tech company Versantis